CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy

  title={CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy},
  author={Daniel Rosenblum and Anna Gutkin and Ranit Kedmi and Srinivas Ramishetti and Nuphar Veiga and Ashley M. Jacobi and Mollie S. Schubert and Dinorah Friedmann-Morvinski and Zvi R. Cohen and Mark A. Behlke and Judy Lieberman and Dan Peer},
  journal={Science Advances},
CRISPR lipid nanoparticles promote in vivo therapeutic genome editing in two aggressive cancer mouse models. Harnessing CRISPR-Cas9 technology for cancer therapeutics has been hampered by low editing efficiency in tumors and potential toxicity of existing delivery systems. Here, we describe a safe and efficient lipid nanoparticle (LNP) for the delivery of Cas9 mRNA and sgRNAs that use a novel amino-ionizable lipid. A single intracerebral injection of CRISPR-LNPs against PLK1 (sgPLK1-cLNPs) into… 

Lipid-based nanocarrier mediated CRISPR/Cas9 delivery for cancer therapy.

The design and genome editing application in cancer therapy has been discussed along with the future concern and prospects of lipid nanoparticle based CRISPR/Cas9 has been focused toward the end.

Blood-brain barrier–penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy

The new CRISPR-Cas9 delivery system addresses various delivery challenges to demonstrate safe and tumor-specific delivery of gene editing Cas9 ribonucleoprotein for improved glioblastoma treatment that may potentially be therapeutically useful in other brain diseases.

A targeting delivery system for effective genome editing in leukemia cells to reverse malignancy.

Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors

It is hoped that this review will provide a novel insight into the CRISPR/Cas9 system and offer guidance for nanocarrier designs that will enable its use in cancer clinical applications.

Genome Editing Approaches with CRISPR/Cas9 for Cancer Treatment: Critical Appraisal of Preclinical and Clinical Utility, Challenges, and Future Research

Preclinical studies and clinical trials that use CRISPR-based technology for therapeutic purposes of cancer and a summary of the presented studies adds a more focused view of the therapeutic value CRISpr/Cas9 holds and the associated shortcomings.

Therapeutic Gene Silencing Using Targeted Lipid Nanoparticles in Metastatic Ovarian Cancer.

In advanced orthotopic ovarian cancer model, intraperitoneal administration of LNPs demonstrates CD44 specific tumor targeting of tNPs compared to uNPs and robust gene silencing in tissues involved in ovarian cancer pathophysiology.

Pre-clinical non-viral vectors exploited for in vivo CRISPR/Cas9 gene editing: an overview.

A brief history and principles of nuclease-mediated gene editing is provided, then a focus on the different CRISPR/Cas9 formats outlining their potentials and limitations are focused on, and the alternative non-viral delivery strategies currently adopted for in vivo CRISpr/ Cas9 gene editing are discussed.

Targeting Cancer with CRISPR/Cas9-Based Therapy

Recent advancements in cancer-selective treatments based on the CRISPR/Cas9 system are described, especially focusing on strategies for targeted delivery of the CRisPR/cas9 machinery to affected cells, controlling Cas9 expression in tissues of interest and disrupting cancer-specific genes to result in selective death of malignant cells.

Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing




Lipid nanoparticle-mediated efficient delivery of CRISPR/Cas9 for tumor therapy

A novel polyethylene glycol phospholipid-modified cationic lipid nanoparticle (PLNP)-based delivery system that can condense and encapsulate a Cas9/single-guide RNA (sgRNA) plasmid (DNA) to form a core–shell structure (PL NP/DNA) that mediated up to 47.4% successful transfection of Cas9 /sgPLK-1 plasmids in A375 cells in vitro.

Selective ORgan Targeting (SORT) nanoparticles for tissue specific mRNA delivery and CRISPR/Cas gene editing

Selective organ targeting (SORT) wherein multiple classes of lipid nanoparticles are systematically engineered to exclusively edit extrahepatic tissues via addition of a supplemental SORT molecule is reported.

Tissue-restricted Genome Editing in vivo Specified by MicroRNA-repressible Anti-CRISPR Proteins.

This strategy provides safeguards against off-tissue genome editing by confining Cas9 activity to selected cell types by establishing a flexible platform in which an Acr transgene is repressed by endogenous, tissue-specific microRNAs (miRNAs).

Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes

A precision protein expression strategy is presented in Ly6c+ inflammatory leukocytes in inflammatory bowel disease (IBD) induced mice and a therapeutic effect in an IBD model by targeted expression of the interleukin 10 is demonstrated.

Enhanced Delivery of Oncolytic Adenovirus by Neural Stem Cells for Treatment of Metastatic Ovarian Cancer

Rational designs of in vivo CRISPR-Cas delivery systems.

apid and highly efficient mammalian cell engineering via as 9 protein transfection

Methods for rapid synthesis of gRNA and for delivery of Cas9 protein/gRNA ribonucleoprotein complexes (Cas9 RNPs) into a variety of mammalian cells through liposome-mediated transfection or electroporation are described.

Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing

This Account focuses on the delivery aspects of CRISPR/Cas for therapeutic applications in vivo, and suggests that current trends seem to favor the use of sgRNA/Cas ribonucleoprotein complexes delivered in vivo by synthetic particles.